Robert Weisman

Weisman covers the healthcare and life sciences industries for the Business section. He was a business reporter and editor for the Hartford Courant and the Seattle Times before joining the Globe in 2000.

Latest stories

China likes what it sees in Boston biotech

By , Globe Staff

Qilu Pharmaceutical Co. has opened the area’s first Chinese-owned biotech incubator. Expect more to follow.

Five things you should know about Shirley Wu

By , Globe Staff

Wu, director of product science at 23andMe, leads the team that creates the personal genomics company’s genetic health risk reports.

Novartis eliminating 11 data jobs in Cambridge

By , Globe Staff

Pharmaceutical giant Novartis AG will cut 11 data management and statistical programming jobs in Cambridge as part of a broader restructuring that will consolidate data operations for the company’s global drug development business in Hyderabad, India.

Biogen spinoff will pay $400m for Calif. drug developer

By , Globe Staff

A hemophilia drug company spun off by Biogen Inc. said it will pay $400 million upfront to buy a California company.